Mio Yamashima

Nagasaki, 8508555, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Association Between Sarcopenic Obesity-Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional Study.

Association Between Sarcopenic Obesity-Related Scores and Liver Fibrosis in Patients with Steatotic Liver Disease: A Cross-Sectional Study.

Journal: Diagnostics (Basel, Switzerland)

Published: November 05, 2025

Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease.

Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease.

Journal: World journal of hepatology

Published: June 13, 2025

Impact of weight loss and lifestyle modifications on liver fibrosis in MASLD and MetALD: A cohort study.

Impact of weight loss and lifestyle modifications on liver fibrosis in MASLD and MetALD: A cohort study.

Journal: Biomedical reports

Published: March 12, 2025

Grip strength is a strong indicator of osteoporosis in both women and men with chronic liver disease.

Grip strength is a strong indicator of osteoporosis in both women and men with chronic liver disease.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 26, 2024

Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3.

Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3.

Journal: Internal medicine (Tokyo, Japan)

Published: September 18, 2024

Serum immunoglobulin A levels: Diagnostic utility in alcoholic liver disease and association with liver fibrosis in steatotic liver disease.

Serum immunoglobulin A levels: Diagnostic utility in alcoholic liver disease and association with liver fibrosis in steatotic liver disease.

Journal: Biomedical reports

Published: May 15, 2024

Non-liver-related mortality in the DAA era: Insights from post-SVR patients with and without previous HCC history.

Non-liver-related mortality in the DAA era: Insights from post-SVR patients with and without previous HCC history.

Journal: Journal of medical virology

Published: August 31, 2023

PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver disease.

PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver disease.

Journal: Biomedical reports

Published: February 14, 2023

Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C.

Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C.

Journal: Biomedical reports

Published: May 26, 2022

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.

Journal: Cancers

Published: January 16, 2022

Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide.

Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide.

Journal: Biomedical reports

Published: August 11, 2021

Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus.

Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus.

Journal: Internal medicine (Tokyo, Japan)

Published: November 02, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026